(Q35364406)

English

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

phase III clinical trial

0 references

Clostridium difficile

0 references

6

object named as

Dale N Gerding

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ellie J. C. Goldstein

1

object named as

Ellie J C Goldstein

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Diane M. Citron

2

object named as

Diane M Citron

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

author name string

Pamela Sears

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Farah Babakhani

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Susan P Sambol

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

0 references

publication date

15 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

5194-5199

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Fidaxomicin versus vancomycin for Clostridium difficile infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

The changing epidemiology of Clostridium difficile infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

Antimicrobial resistance in Clostridium difficile.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

Metronidazole resistance in Clostridium difficile is heterogeneous

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

In vitro activity of OPT-80 against Clostridium difficile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

12 July 2018

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

26 September 2018

Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195051

26 September 2018

Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action

1 reference

https://pubmed.ncbi.nlm.nih.gov/21844318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin

1 reference

https://pubmed.ncbi.nlm.nih.gov/21844318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clostridium difficile infection in Ohio hospitals and nursing homes during 2006

1 reference

https://pubmed.ncbi.nlm.nih.gov/21844318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.00625-11

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35364406&oldid=2068525813"